Sigrid Therapeutics
Stockholm, Sweden · Biotechnology · 17 employees
Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising worldwide. Each year 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease. Sigrid is a clinical-stage biotech company driven by the vision to improve human health through material-based innovations. We are pioneering a new class of
Funding history
- Funding Round — $5.0M — Jan 2026
- Series seed — $4.0M — Oct 2023
- Series seed — $10.6M — Jan 2023
Recent signals
- Jan 28, 2026: Sigrid Therapeutics Appoints Claus Kjaersgaard as Chief Executive Officer
- Jan 07, 2026: Raised $5.0M
- Oct 31, 2023: Raised $4.0M in Series seed
- Jan 16, 2023: Raised $10.6M in Series seed
See plans & pricing → Track Sigrid Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.